Blood test of p-tau217 showed a similar or better ability in detecting Alzheimer’s disease-related structure changes in the brains of individuals with impaired cognitive ability, compared with cerebrospinal fluid test. The researchers suggest that p-tau217 blood test may replace positron emission tomography or cerebrospinal fluid test, the methods currently used in research and the clinic. […]
GFAP, a Strong Blood-based Biomarker, Predicted Alzheimer’s Disease at Least 10 Years Before Symptoms Appear
Researchers have found that by evaluating people’s blood levels of glial fibrillary acidic protein (GFAP), together with their cognitive test results and demographic information, they could predict Alzheimer’s disease at least 10 years before the diagnosis. The prediction was more accurate when they considered all these factors together, rather than considering the blood level of GFAP alone. […]
Read Time:
6 Min
GFAP Predicts Cognitive Worsening of Patients with Impaired Cognitive Ability
A cohort study of patients with impaired cognitive ability suggested that glial fibrillary acidic protein (GFAP), a potential blood-based biological marker, also called biomarker, can predict decline of cognitive ability associated with Alzheimer’s disease. This study showed the power of blood GFAP in predicting cognitive decline among patients with impaired cognitive ability. Current methods used […]
Read Time:
5 Min
Increased Blood Levels of GFAP May Track Alzheimer’s Disease Progression Before Cognitive Symptoms Occur
In a study with people who had normal cognitive ability, researchers found that the blood levels of glial fibrillary acidic protein (GFAP) increased more rapidly in people at risk of future Alzheimer’s disease than those without the risk of the disease. Protein GFAP locates in the cells that support the nerve cells in the central […]
Read Time:
5 Min